This report covers:
- The total funding raised for Series A rounds in the last 6 years.
- Trends in upfront licensing payments illustrating the continued faith in biologicals over advanced therapeutics.
- The fluctuations in market activity, with Q1 2024 marking a significant resurgence in biopharma IPOs despite a quieter start in terms of overall deal numbers compared to the previous year.
- Additionally, we present a comparative study of the number and types of deals in Q1 2023 versus Q1 2024, offering a snapshot of the evolving investment landscape.
Stay ahead of the curve and enhance your investment strategy with insights from our comprehensive report.
Download Here
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
